Also, this interaction between ANGPTL4 and SUA-related lipid disturbance creates the possibility for ANGPTL4-targeted therapies to impart a significant benefit in hyperuricemia-associated dyslipidemia. Here, ANGPTL4 is linked to metabolic syndrome.